+

WO2001021167A8 - Traitement des symptomes des voies urinaires basses, et compositions pharmaceutiques a utiliser dans le cadre dudit traitement - Google Patents

Traitement des symptomes des voies urinaires basses, et compositions pharmaceutiques a utiliser dans le cadre dudit traitement

Info

Publication number
WO2001021167A8
WO2001021167A8 PCT/US2000/025534 US0025534W WO0121167A8 WO 2001021167 A8 WO2001021167 A8 WO 2001021167A8 US 0025534 W US0025534 W US 0025534W WO 0121167 A8 WO0121167 A8 WO 0121167A8
Authority
WO
WIPO (PCT)
Prior art keywords
urinary tract
lower urinary
treatment
tract symptoms
pharmaceutical compositions
Prior art date
Application number
PCT/US2000/025534
Other languages
English (en)
Other versions
WO2001021167A1 (fr
Inventor
Elizabeth Stoner
Paul J Drake
Mark A Bach
Original Assignee
Merck & Co Inc
Elizabeth Stoner
Paul J Drake
Mark A Bach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Elizabeth Stoner, Paul J Drake, Mark A Bach filed Critical Merck & Co Inc
Priority to AU77037/00A priority Critical patent/AU7703700A/en
Publication of WO2001021167A1 publication Critical patent/WO2001021167A1/fr
Publication of WO2001021167A8 publication Critical patent/WO2001021167A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne le traitement d'un état médical, touchant les hommes, connu sous le nom de symptômes des voies urinaires basses par l'administration d'un antagoniste du récepteur muscarinique en association avec un inhibiteur de 5α-réductase au moins et un agent de blocage du récepteur α-adrénergique.
PCT/US2000/025534 1999-09-22 2000-09-18 Traitement des symptomes des voies urinaires basses, et compositions pharmaceutiques a utiliser dans le cadre dudit traitement WO2001021167A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU77037/00A AU7703700A (en) 1999-09-22 2000-09-18 Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15535799P 1999-09-22 1999-09-22
US60/155,357 1999-09-22

Publications (2)

Publication Number Publication Date
WO2001021167A1 WO2001021167A1 (fr) 2001-03-29
WO2001021167A8 true WO2001021167A8 (fr) 2001-09-07

Family

ID=22555118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025534 WO2001021167A1 (fr) 1999-09-22 2000-09-18 Traitement des symptomes des voies urinaires basses, et compositions pharmaceutiques a utiliser dans le cadre dudit traitement

Country Status (2)

Country Link
AU (1) AU7703700A (fr)
WO (1) WO2001021167A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141235A (en) 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
EP1438035A2 (fr) * 2001-09-27 2004-07-21 Pharmacia AB Compositions pharmaceutiques pour le traitement de troubles urinaires
WO2003090753A1 (fr) * 2002-04-24 2003-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combinaison pharmaceutique pour le traitement de l'hyperplasie prostatique benigne ou pour la prevention a long terme de la retention urinaire aigue
WO2005092341A1 (fr) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Therapie combinee destinee a reduire les symptomes des voies urinaires
MX2007003949A (es) * 2007-04-02 2009-02-25 World Trade Imp Export Wtie Ag Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima (-reductasa y un antagonista de los receptores 1 (-adrenergicos.
US20110262566A1 (en) * 2008-11-07 2011-10-27 Dainippon Sumitomo Pharma Co., Ltd. Novel useful therapeutic agent for lower urinary tract symptom

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770221A (en) * 1994-05-18 1998-06-23 Hisamitsu Pharmaceutical Co., Inc. Formulation for percutaneous administration for treating disturbance in micturition

Also Published As

Publication number Publication date
WO2001021167A1 (fr) 2001-03-29
AU7703700A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
WO2004052348A3 (fr) Traitement de maladies a l'aide de combinaisons d'agonistes du recepteur nicotinique de l'acetylcholine alpha 7 et d'autres composes
CA2334460A1 (fr) Compositions pharmaceutiques comprenant des antagonistes alpha-adrenorecepteur et muscarinique
EP1020190A3 (fr) Traitement de l' hyperplasie prostatique benigne avec des élévateurs du cGMP
AU2002322478A1 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
EP1600168A3 (fr) Dérivé de pyrrolidine acetamide, seul ou en combinaison, pour le traitement des maladies du système nerveux central
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2001037785A3 (fr) Nouveaux procedes et nouvelles compositions comprenant des opioides et des antagonistes d'opioides
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
WO2003011117A3 (fr) Techniques et compositions destinees au traitement et a la prevention de lesions de la partie distale de l'intestin
AU2855399A (en) Vascularization inhibitors
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
TWI340639B (en) Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph
WO2006074265A3 (fr) Therapie combinee et compositions pharmaceutiques utilisees dans le traitement des troubles inflammatoires
WO2001062235A3 (fr) Composition comprenant la camptothecine et un derive de pyrimidine et destinee a etre utilisee dans le traitement du cancer
AU7360700A (en) Methods and compositions for preventing and treating urinary tract disorders
WO2001021167A8 (fr) Traitement des symptomes des voies urinaires basses, et compositions pharmaceutiques a utiliser dans le cadre dudit traitement
AU2003290015A1 (en) Mastitis treatment
WO2000053148A3 (fr) Procedes et compositions pour le traitement de la dyserection
AU1604001A (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
WO2005009340A3 (fr) Procedes destines au traitement ou a la prevention de troubles respiratoires avec un inhibiteur de cyclooxygenase-2 utilise en combinaison avec un antagoniste de recepteur muscarinique et composition les contenant
UA86802C2 (ru) Комбинация симетикона и бисакодила для предрасположенных к запору пациентов, которые страдают от ощущения вздутия живота
WO2005070460A3 (fr) Polytherapie au moyen d'antagonistes des recepteurs 5-ht1a et 5-ht1b

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载